Familial Hypertrophic Cardiomyopathy: From Mutations to Functional Defects

作者: Gisèle Bonne , Lucie Carrier , Pascale Richard , Bernard Hainque , Ketty Schwartz

DOI: 10.1161/01.RES.83.6.580

关键词:

摘要: Hypertrophic cardiomyopathy is characterized by left and/or right ventricular hypertrophy, which usually asymmetric and involves the interventricular septum. Typical morphological changes include myocyte hypertrophy disarray surrounding areas of increased loose connective tissue. Arrhythmias premature sudden deaths are common. familial in majority cases transmitted as an autosomal-dominant trait. The results molecular genetics studies have shown that hypertrophic a disease sarcomere involving mutations 7 different genes encoding proteins myofibrillar apparatus: ss-myosin heavy chain, myosin essential light regulatory cardiac troponin T, I, alpha-tropomyosin, binding protein C. In addition to this locus heterogeneity, there wide allelic since numerous been found all these genes. recent development animal models vitro analyses allowed better understanding pathophysiological mechanisms associated with cardiomyopathy. One can thus tentatively draw following cascade events: mutation leads poison polypeptide would be incorporated into sarcomere. This alter sarcomeric function result (1) altered then (2) alteration structure. Some induce functional impairment support pathogenesis hypothesis "hypocontractile" state followed compensatory hypertrophy. Other hyperfunction determine "hypercontractile" directly other mechanistic linking genetic defects now key issues how alterations basic contractile unit cardiomyocyte phenotype heart.

参考文章(136)
Barry J. Maron, Robert O. Bonow, Richard O. Cannon, Martin B. Leon, Stephen E. Epstein, Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). The New England Journal of Medicine. ,vol. 316, pp. 780- 789 ,(1987) , 10.1056/NEJM198703263161305
GIOVANNI CUDA, LAMEH FANANAPAZIR, NEAL D. EPSTEIN, JAMES R. SELLERS, The in vitro motility activity of β-cardiac myosin depends on the nature of the β-myosin heavy chain gene mutation in hypertrophic cardiomyopathy Journal of Muscle Research and Cell Motility. ,vol. 18, pp. 275- 283 ,(1997) , 10.1023/A:1018613907574
Robert M. Hamilton, Developmental mechanisms of heart disease Critical Care Medicine. ,vol. 25, pp. 206- ,(1997) , 10.1097/00003246-199701000-00040
Karen L. Vikstrom, Stephen M. Factor, Leslie A. Leinwand, Mice Expressing Mutant Myosin Heavy Chains Are a Model for Familial Hypertrophic Cardiomyopathy Molecular Medicine. ,vol. 2, pp. 556- 567 ,(1996) , 10.1007/BF03401640
P J Barton, A Cohen, B Robert, M Y Fiszman, F Bonhomme, J L Guénet, D P Leader, M E Buckingham, The myosin alkali light chains of mouse ventricular and slow skeletal muscle are indistinguishable and are encoded by the same gene. Journal of Biological Chemistry. ,vol. 260, pp. 8578- 8584 ,(1985) , 10.1016/S0021-9258(17)39512-1
H.L. Sweeney, A.J. Straceski, L.A. Leinwand, B.A. Tikunov, L. Faust, Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. Journal of Biological Chemistry. ,vol. 269, pp. 1603- 1605 ,(1994) , 10.1016/S0021-9258(17)42067-9
W L Fodor, B Darras, J Seharaseyon, S Falkenthal, U Francke, E F Vanin, Human Ventricular/Slow Twitch Myosin Alkali Light Chain Gene Characterization, Sequence, and Chromosomal Location Journal of Biological Chemistry. ,vol. 264, pp. 2143- 2149 ,(1989) , 10.1016/S0021-9258(18)94153-0